EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates

MT Newswires Live

2025/06/02

EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.

The treatment candidates are in oral formulations, developed by Nextract.

Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.

The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.

EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540750039"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540750039\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540750039?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540750039","market":"fut","top_or_hot":-1,"title":"EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates","media":"MT Newswires Live","content":"<html><body><p> EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.</p><p>The treatment candidates are in oral formulations, developed by Nextract.</p><p>Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.</p><p>The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.</p><p>EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-02 14:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.</p><p>The treatment candidates are in oral formulations, developed by Nextract.</p><p>Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.</p><p>The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.</p><p>EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7141","symbol_name":"包裝食品與肉類","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540750039","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540750039","pubTimestamp":1748846483,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EVE Health Group  said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.The treatment candidates are in oral formulations, developed by Nextract.Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7141":"包装食品与肉类","EVE.AU":"Eve Health Ltd","EVE":"EVe Mobility Acquisition Corp"},"translate_title":"EVE Health Group开始对勃起功能障碍、痛经候选人进行稳定性测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVE":1,"EVE.AU":0.9},"content_text":"EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.The treatment candidates are in oral formulations, developed by Nextract.Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}